Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,139 Mln
Revenue (TTM)
$1,255 Mln
Net Profit (TTM)
$0 Mln
ROE
-9 %
ROCE
-- %
P/E Ratio
2.6
P/B Ratio
49.5
Industry P/E
--
EV/EBITDA
1.1
Div. Yield
0 %
Debt to Equity
-2.2
Book Value
$--
EPS
$2.6
Face value
--
Shares outstanding
161,970,000
CFO
$-1,761.81 Mln
EBITDA
$-4,055.75 Mln
Net Profit
$-4,392.73 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Novavax (NVAX)
| -21.6 | -6.4 | -24.8 | -55.2 | -46.1 | -35.3 | -28.6 |
|
BSE Sensex*
| 4.1 | -1.1 | 8.1 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Novavax (NVAX)
| 66.8 | -53.3 | -92.8 | 28.3 | 2,701.8 | -89.2 | 48.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Novavax (NVAX)
|
6.3 | 1,138.7 | 1,255.0 | 478.7 | -1.2 | -- | 2.6 | 49.5 |
| 50.1 | 8,093.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 61.9 | 4.0 | |
| 128.1 | 8,293.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 145.3 | 7,417.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.3 | 10,095.9 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 40.7 | 11,385.6 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19 | 5.3 | |
| 302.7 | 8,650.6 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23 | 14.4 | |
| 25.4 | 10,055.3 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,370.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.3 | 4.9 | |
| 291.7 | 13,016.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.5 | 1.9 |
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that... combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Address: 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878 Read more
President & COO
Mr. John Joseph Trizzino B.S., M.B.A.
President & COO
Mr. John Joseph Trizzino B.S., M.B.A.
Headquarters
Gaithersburg, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Novavax Inc (NVAX) stood at $ 1,715 Mln as on 31-Mar-25
The share price of Novavax Inc (NVAX) is $6.30 (NASDAQ) as of 18-Jun-2025 16:26 EDT. Novavax Inc (NVAX) has given a return of -46.1% in the last 3 years.
Novavax Inc (NVAX) has a market capitalisation of $ 1,139 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Novavax Inc (NVAX) is 49.52 times as on 18-Jun-2025, a 1701% premium to its peers’ median range of 2.75 times.
The P/E ratio of Novavax Inc (NVAX) is 2.56 times as on 18-Jun-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Novavax Inc (NVAX) and enter the required number of quantities and click on buy to purchase the shares of Novavax Inc (NVAX).
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Address: 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878
The CEO & director of Mr. John Joseph Trizzino B.S., M.B.A.. is Novavax Inc (NVAX), and CFO & Sr. VP is Mr. John Joseph Trizzino B.S., M.B.A..
There is no promoter pledging in Novavax Inc (NVAX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Novavax Inc. (NVAX) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-1.22
|
|
Net Margin(%)
|
38.14
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Novavax Inc (NVAX) was $0 Mln.
$-0.19
(
